fig4

Figure 4. Comprehensive mRNA sequencing analysis of UCMSC-NV-mediated gene expression and pathway modulations in ALI. (A) PCoA visualizing the distribution among various mouse cohorts; (B) Volcano plots illustrating DEGs between the LPS and control groups, as well as between the LPS and UCMSC-NV treated groups; (C) GO enrichment analysis conducted for the LPS vs. control group comparison; (D) GO enrichment analysis for the LPS vs. UCMSC-NV group comparison; (E) KEGG pathway enrichment depicting pathways influenced by LPS exposure; (F) KEGG pathway enrichment identifying pathways modulated by UCMSC-NV treatment; (G) Heatmap depicting the expression fluctuations of key factors. mRNA: Messenger RNA; UCMSC-NV: nanovesicles originating from human umbilical cord mesenchymal stem cell; ALI: acute lung injury; PCoA: principal coordinate analysis; DEGs: differentially expressed genes; LPS: lipopolysaccharide; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; DA: dopamine; BP: biological process; MF: molecular function; CC: cellular component; MAPK: mitogen-activated protein kinase; cGMP: cyclic guanosine monophosphate; TNF: tumor necrosis factor; NOD: nucleotide-binding oligomerization domain; NF: nuclear factor; IL-17: interleukin-17.